IBRXImmunityBio, Inc.

Nasdaq immunitybio.com


$ 3.45 $ -0.15 (-4.29 %)    

Monday, 16-Sep-2024 15:54:00 EDT
QQQ $ 473.37 $ 0.31 (0.07 %)
DIA $ 417.53 $ 2.59 (0.62 %)
SPY $ 562.92 $ 1.45 (0.26 %)
TLT $ 101.29 $ 0.67 (0.66 %)
GLD $ 238.65 $ 0.05 (0.02 %)
$ 3.58
$ 3.61
$ 3.45 x 2,037
$ 3.46 x 2,185
$ 3.43 - $ 3.64
$ 1.25 - $ 10.53
2,206,901
na
2.49B
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-19-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-07-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-25-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-06-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-13-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-06-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 03-15-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-16-2016 03-31-2016 10-Q
35 03-30-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 09-10-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunitybio-presents-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy-at-world-conference-on-lung-cancer

Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in ...

 piper-sandler-maintains-neutral-on-immunitybio-lowers-price-target-to-475

Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and lowers the price target from $...

 immunitybios-anktiva-now-available-to-patients-through-both-commercial-and-government-insurance-programs-also-announced-plans-to-expand-its-bladder-cancer-program-globally-notably-in-the-european-union-and-india

  ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval

 immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer

The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for ...

 chinas-bilibili-and-ollies-bargain-outlet-were-among-10-mid-cap-stocks-with-biggest-gains-in-the-last-week-june-16-june-22-2024-are-they-in-your-portfolio

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...

 why-immunitybio-stock-is-trading-higher-thursday

The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was...

 immunitybio-announces-insurance-coverage-of-anktiva-across-multiple-states-with-first-commercial-doses-administered

Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immu...

 immunitybio-completes-gmp-drug-substance-manufacturing-sufficient-for-170000-doses-of-anktiva

ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA pro...

 serum-institute-of-india-inks-large-scale-supply-deal-for-bcg-use-in-immunitybios-bladder-cancer-combo-therapy

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION